A novel dual inhibitor of microtubule and Bruton’s Tyrosine Kinase inhibits survival of multiple myeloma and osteoclastogenesis.
Pandey MK et al. Exp Hematol. 2017 Jun 21. pii: S0301-472X(17)30233-3. doi: 10.1016/j.exphem.2017.06.003. [Epub ahead of print].
Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma.
Laganà A et al. Leukemia. 2017 Jun 23. doi: 10.1038/leu.2017.197. [Epub ahead of print].
Changes in uninvolved immunoglobulins during induction therapy for newly diagnosed multiple myeloma.
Ravi P et al. Blood Cancer J. 2017 Jun 16;7(6):e569. doi: 10.1038/bcj.2017.46
Will we be able to afford a cure in multiple myeloma?
Chakraborty R et al. Leuk Lymphoma. 2017 Jun 20:1-2. doi: 10.1080/10428194.2017.1339883. [Epub ahead of print].
Anti-Myeloma effects of ruxolitinib combined with bortezomib and lenalidomide: A rationale for jak/stat pathway inhibition in myeloma patients.
de Oliveira MB et al. Cancer Lett. 2017 Jun 20. pii: S0304-3835(17)30398-1. doi: 10.1016/j.canlet.2017.06.016. [Epub ahead of print].
Raman spectroscopy differentiates between sensitive and resistant multiple myeloma cell lines.
Franco D et al. Spectrochim Acta A Mol Biomol Spectrosc. 2017 Jun 15;187:15-22. doi: 10.1016/j.saa.2017.06.020. [Epub ahead of print].
MUC1-C is a target in lenalidomide resistant multiple myeloma.
Yin L et al. Br J Haematol. 2017 Jun 23. doi: 10.1111/bjh.14801. [Epub ahead of print].
Adoptive cell therapy using PD-1+ myeloma-reactive T cells eliminates established myeloma in mice.
Jing W et al. J Immunother Cancer. 2017 Jun 20;5:51. doi: 10.1186/s40425-017-0256-z. eCollection 2017.
NY-ESO-1 TCR single edited central memory and memory stem T cells to treat multiple myeloma without inducing GvHD.
Mastaglio S et al. Blood. 2017 Jun 21. pii: blood-2016-08-732636. doi: 10.1182/blood-2016-08-732636. [Epub ahead of print].
Novel tropolones induce the unfolded protein response pathway and apoptosis in multiple myeloma cells.
Haney SL et al. Oncotarget. 2017 Jun 16. doi: 10.18632/oncotarget.18543. [Epub ahead of print].
Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair.
López-Iglesias AA et al. J Hematol Oncol. 2017 Jun 20;10(1):127. doi: 10.1186/s13045-017-0495-y.
Therapeutic effects of CSF1R-blocking antibodies in multiple myeloma.
Wang Q et al. Leukemia. 2017 Jun 19. doi: 10.1038/leu.2017.193. [Epub ahead of print].
Role of epigenetics-microRNA axis in drug resistance of multiple myeloma.
Rastgoo N et al. J Hematol Oncol. 2017 Jun 17;10(1):121. doi: 10.1186/s13045-017-0492-1.
Loss of FAM46C promotes cell survival in myeloma.
Zhu YX et al. Cancer Res. 2017 Jun 15. pii: canres.3011.2016. doi: 10.1158/0008-5472.CAN-16-3011. [Epub ahead of print].
The germline factor DDX4 functions in blood-derived cancer cell phenotypes.
Schudrowitz N et al. Cancer Sci. 2017 Jun 14. doi: 10.1111/cas.13299. [Epub ahead of print].
Kinesin-5 Blocker Monastrol Protects Against Bortezomib-Induced Peripheral Neurotoxicity.
Bobylev I et al. Neurotox Res. 2017 Jun 13. doi: 10.1007/s12640-017-9760-7. [Epub ahead of print].
ATF3 repression of BCL-XL determines apoptotic sensitivity toHDAC inhibitors across tumour types.
Chüeh AC et al. Clin Cancer Res. 2017 Jun 13. pii: clincanres.0466.2017. doi: 10.1158/1078-0432.CCR-17-0466. [Epub ahead of print].
Overcoming multiple myeloma drug resistance in the era of cancer ‘omics’.
Guang MHZ et al.Leuk Lymphoma. 2017 Jun 13:1-20. doi: 10.1080/10428194.2017.1337115. [Epub ahead of print].
Targeting autophagy in multiple myeloma.
Yun Z et al. Leuk Res. 2017 Jun 3;59:97-104. doi: 10.1016/j.leukres.2017.06.002. [Epub ahead of print].
Endothelin-1 receptor blockade as new possible therapeutic approach in multiple myeloma.
Russignan A et al. Br J Haematol. 2017 Jun 9. doi: 10.1111/bjh.14771. [Epub ahead of print].
Nucleotide excision repair (NER) is a potential therapeutic target in multiple myeloma.
Szalat R et al. Leukemia. 2017 Jun 7. doi: 10.1038/leu.2017.182. [Epub ahead of print].
Blockade of deubiquitylating enzyme Rpn11 triggers apoptosis in multiple myeloma cells and overcomes bortezomib resistance.
Song Y et al. Oncogene. 2017 Jun 5. doi: 10.1038/onc.2017.172. [Epub ahead of print].
MTI-101 treatment inducing activation of Stim1 and TRPC1 expression is a determinant of response in multiple myeloma.
Emmons MF et al. Sci Rep. 2017 Jun 2;7(1):2685. doi: 10.1038/s41598-017-02713-0.
Successful treatment with azacitidine for the simultaneous occurrence of multiple myeloma and acute myeloid leukemia with concomitant del(5q) and the JAK2 V617F mutation.
Oka S et al. Ann Hematol. 2017 Aug;96(8):1411-1413. doi: 10.1007/s00277-017-3032-8. Epub 2017 Jun 2.
The blueberry component pterostilbene has potent anti-myeloma activity in bortezomib-resistant cells.
Chen G et al. Oncol Rep. 2017 Jul;38(1):488-496. doi: 10.3892/or.2017.5675. Epub 2017 May 30.